Axogen, Inc.
0HKD.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.94B
Close$
$-15.84
142.8% downside
Current Fair Value
142.8% downsideOvervalued by 142.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.94 Billion |
|---|---|
| Enterprise Value | $1.87 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.34 |
| Beta | 1.14 |
| Outstanding Shares | 53,339,258 |
Return
| Return on Equity | -13.09% |
|---|---|
| Return on Assets | -11.00% |
| Return on Invested Capital | -5.09% |
Valuation & Multiples
| P/E Ratio | -53.54 |
|---|---|
| PEG | 14.8 |
| Price to Sales | 9.25 |
| Price to Book Ratio | 9.25 |
| Enterprise Value to Revenue | 7.44 |
| Enterprise Value to EBIT | -133.79 |
| Enterprise Value to Net Income | -56 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 29, 2026
EPS Estimate
$0.12
Average shareholder expectationRevenue Estimate
$67.10 M
Average shareholder expectationNext Earnings Call
Expected Date
October 28, 2026
EPS Estimate
$0.13
Average shareholder expectationRevenue Estimate
$73.23 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Axogen Inc.
622 employees
CEO: Michael D. Dale Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allo...